Semaglutide significantly reduces cardiovascular events and adverse effects in overweight and obese patients. The study highlights semaglutide's superiority over other GLP-1 agonists for cardiovascular health.
By Dr. Liji Thomas, MDOct 14 2024 Study shows that semaglutide not only aids in weight loss but also slashes heart failure risk by 76% in overweight patients—though higher doses bring notable side effects.
In 2020, there were 2.6 billion obese or overweight people worldwide, with the number predicted to hit four billion by 2035. Cardiovascular disease is the major cause of death in this population. GLP-1 receptor agonists, including semaglutide, are increasingly used for this population due to their potential to reduce both weight and cardiovascular events.
Previous research indicated a 22% improvement in cardiovascular outcomes, suggesting other modes of action of GLP-1 agonists. Among these, semaglutide stands out as the most extensively studied. The current study aimed to understand how far it improves cardiovascular outcomes and its adverse effects .
Improved cardiovascular outcomes The results showed that patients on semaglutide were 76% less likely to be hospitalized for heart failure than controls. However, this effect was primarily observed in patients without diabetes. The risk of death from CVD fell by 17%. Adverse effects analysis Treatment discontinuation was twice as likely with both subcutaneous and oral semaglutide vs. controls.
Semaglutide Agonist AIDS Blood Blood Pressure Cardiovascular Disease Cholesterol Constipation Diabetes Diarrhea GLP-1 Glucagon Glucose Hba1c Heart Failure Insulin Nausea Obesity Placebo Receptor Research Stroke Vomiting Weight Loss
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Semaglutide shows promise in treating chronic skin condition in obese patientsA pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity.
Read more »
Semaglutide improves outcomes for obese patients with common skin condition, new study showsA pioneering study, presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity.
Read more »
Study links semaglutide to reduced opioid overdose risk in patients with OUD and diabetesSince being deemed a public health emergency in 2017, opioids are responsible for 72% of drug overdose deaths in the United States, according to the National Center for Drug Abuse Statistics.
Read more »
How Does Semaglutide Work to Lose Weight?Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for obesity and type 2 diabetes management.
Read more »
Novel procedure combined with semaglutide may eliminate insulin dependency in type 2 diabetesGroundbreaking research presented at UEG Week 2024 reveals a promising new treatment strategy for type 2 diabetes (T2D) that could significantly reduce or even eliminate the need for insulin therapy.
Read more »
Study shows bariatric surgery outperforms GLP-1 diabetes drugs for kidney protectionA Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery was associated with a significant decrease in the progression of chronic kidney disease compared to those who received GLP-1 diabetes medications. The paper was published in Annals of Surgery.
Read more »